Trial Profile
A Phase 2a Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability of a Single Intravenous Dose of an Investigational Monoclonal Antibody With Code Name VIS410 in Subjects With Uncomplicated Influenza A Infection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Aug 2022
Price :
$35
*
At a glance
- Drugs VIS 410 (Primary)
- Indications Influenza A virus infections
- Focus Adverse reactions
- Sponsors Visterra
- 15 Nov 2018 According to a Visterra media release, data from the study were presented at the 6th International Society for Influenza and other Respiratory Virus Diseases (ISIRV) Advances in Respiratory Virus Therapeutics Conference.
- 15 Nov 2018 Results published in the Media Release
- 13 Dec 2017 Status changed from active, no longer recruiting to completed.